Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Thera SolutionsSHSE:688177 -3.38%57 Gross Margin % is 81.34% as of Mar. 2026, which is 12% above its 10-year median of 72.57. GuruFocus rates SHSE:688177 with a GF Score™ of 57/100 and a GF Value™ of ¥33.46 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 733 Biotechnology companies, Bio-Thera Solutions ranks better than 72.44% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bio-Thera Solutions had a gross margin of 81.34% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bio-Thera Solutions Gross Margin % Related Terms
Bio-Thera Solutions Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bio-Thera Solutions's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688177 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Bio-Thera Solutions's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Thera Solutions Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Thera Solutions's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bio-Thera Solutions's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bio-Thera Solutions (SHSE:688177) has a Gross Margin % of 81.34% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Thera Solutions and its competitors. This is 12% above median its historical median of 72.57. Over the past decade, Bio-Thera Solutions' Gross Margin % has ranged from 30.46 to 95.74. According to the industry distribution chart, Bio-Thera Solutions ranks #202 out of 733 companies in the Biotechnology industry, placing it in the top 27.6%.
Is Bio-Thera Solutions' Gross Margin % too high?
Bio-Thera Solutions' current Gross Margin % of 81.34% is 12% above median its 10-year median of 72.57. Over the past 10 years, this metric has ranged from a low of 30.46 to a high of 95.74. The Biotechnology industry median Gross Margin % is 60.90. Bio-Thera Solutions' value of 81.34% is 33.6% above this industry median. Based on the distribution chart, Bio-Thera Solutions ranks #202 out of 733 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bio-Thera Solutions has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio-Thera Solutions' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bio-Thera Solutions ranks #202 out of 733 companies for Gross Margin %. This puts Bio-Thera Solutions in the upper half of its industry. The industry median Gross Margin % is 60.90. Bio-Thera Solutions' value of 81.34% is 33.6% above this benchmark. Historically, Bio-Thera Solutions' own Gross Margin % has ranged from 30.46 to 95.74 over the past decade. While the company's 10-year median is 72.57 vs. the industry median of 60.90, Bio-Thera Solutions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.90, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Thera Solutions's current Gross Margin % of 81.34% is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bio-Thera Solutions and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Thera Solutions's current Gross Margin % is 81.34%, which is 12% above median its own 10-year median of 72.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Thera Solutions stock overvalued right now?
Based on GuruFocus' analysis, Bio-Thera Solutions (SHSE:688177) is currently considered Possible Value Trap. The stock's GF Value™ is ¥33.46, compared to a current price of ¥16.58 — trading 50.4% below its estimated fair value. The current Gross Margin % is 81.34%, which is 12% above median its 10-year median of 72.57 and 33.6% above the Biotechnology industry median of 60.90. Bio-Thera Solutions' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bio-Thera Solutions (SHSE:688177), the current Gross Margin % is 81.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Thera Solutions (SHSE:688177) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Thera Solutions stock appears to be undervalued.
The current stock price of ¥16.58 is trading 50.4% below its estimated GF Value™ of ¥33.46.
GuruFocus considers Bio-Thera Solutions to be Possible Value Trap.
Key valuation signals for SHSE:688177:
Gross Margin %: 81.34% (12% above median its 10-year median of 72.57)
GF Value™: ¥33.46 vs. price of ¥16.58 (50.4% below fair value)
Industry Position: 33.6% above the Biotechnology median (#202 of 733)
No single metric tells the full story. See the SHSE:688177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
57GF Score
Get the complete analysis for SHSE:688177
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688177 has been successfully added to your 
